Navigation Links
Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
Date:5/22/2008

ting effects. Because of its chemical structure, RELISTOR does not affect the opioid-mediated analgesic effects on the CNS.

About Subcutaneous RELISTOR

On April 24, 2008, the United States Food and Drug Administration approved RELISTOR subcutaneous injection for the treatment of OIC in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. The use of RELISTOR beyond four months has not been studied. Wyeth expects to make subcutaneous RELISTOR available in the United States in early June. Subcutaneous RELISTOR has also been approved in Canada and is awaiting Australian approval and European approval, having received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the EMEA scientific committee, in April.

Important Safety Information for Subcutaneous RELISTOR

-- RELISTOR is contraindicated in patients with known or suspected

mechanical gastrointestinal obstruction.

-- If severe or persistent diarrhea occurs during treatment, advise

patients to discontinue therapy with RELISTOR and consult their

physician.

-- Use of RELISTOR has not been studied in patients with peritoneal

catheters.

-- The most common adverse reactions with RELISTOR in clinical trials were

abdominal pain, flatulence, and nausea.

RELISTOR Prescribing Information is available at http://www.relistor.com.

About the Collaboration

In December 2005, Wyeth and Progenics Pharmaceuticals entered into an exclusive, worldwide agreement for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects.

About the Companies

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous
'/>"/>

SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
3. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
4. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
5. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
6. Wyeths TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer
7. Arthritis Foundation Announces Amgen and Wyeth to Be Presenting Sponsor of the 2008 Arthritis Walk (R)
8. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)... Md., Dec. 1 Vanda Pharm...ion in The Lancet , one of the world,s leading me...novel circadian regulator, experimental compound t...am et al(1) is entitled "Melatonin agonist tasimel...time shift: two randomised controlled multicentre ...
(Date:12/1/2008)...IS, Dec. 1 Roche announced today t...ferences in perceived pain and,discomfort associa...ood,glucose monitoring systems and lancing device...cated that, overall, the ACCU-CHEK Aviva and ACCU-...s and the ACCU-CHEK Multiclix, ACCU-CHEK,Softclix...
(Date:12/1/2008)...inence is still the best policy , , ROCHES...w study from Mayo Clinic finds the use of the drug...lic hepatitis, an acute inflammation of the liver ...sults of the study are published in the December i...nal.org/ ). , , VIDEO ALERT: Additional au...
(Date:12/1/2008)...nce Call Scheduled for Tuesday, December 9 at 11:0... , , SOUTH SAN FRANCISCO, Calif., Dec. 1 ..., Inc. (Nasdaq: SNSS ), a biopharmaceutical comp...on of new oncology therapeutics, today announced n...loid leukemia (AML) will be presented during the 5...
Breaking Medicine Technology:Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 2Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 3Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals' Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet 4Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 2Study Shows ACCU-CHEK(R) Blood Glucose Monitoring Systems and Lancing Devices Are Least Painful 3Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3A bees future as queen or worker may rest with parasitic fly 4223 1A bees future as queen or worker may rest with parasitic fly 4223 2Nu Skin Enterprises and Toyo Bio Pharma Enter Agreement for Joint Product Research and Development 24435 1Nu Skin Enterprises and Toyo Bio Pharma Enter Agreement for Joint Product Research and Development 24435 2Healthcare Executives Well Rewarded for Their Work 24431 1Healthcare Executives Well Rewarded for Their Work 24431 2Hypnosis shown to reduce symptoms of dementia 24427 1
...cokinetics and Dose Proportionality of,Company,s O...tics,Journal -, LAVAL, QC, June 29, 2007 /PRNewswi...t it will present a poster discussing the dose,tit...t the 3rd,International Forum on Pain Medicine to ...a. , The poster compares two different titration s...
...2007: Chi-Med, the Hutchison Whampoa backed pharma...itive results for its Phase II,proof-of-concept st...litis, a form of inflammatory bowel disease. The ...tolerated and showed an,equivalent drop in clinica..., the current first-line standard of care in,mild-...
Other Medicine Technology:Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine 2Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine 3Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 2Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 3Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 4Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 5Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 6Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 7Chi-Med Announces Positive Phase II Proof-of-Concept Data for,HMPL-004 in Ulcerative Colitis 8
(Date:12/2/2008)...es that the SouthEast Alaska Regional Health Conso... Rhapsody™ Integration Engine to help the di...acy, laboratory and business programs communicate ...ity to statewide systems such as VacTrAK (the Stat...MIS and clinical documentation tool used by substa...
(Date:12/2/2008)...Population Services International (PSI) is launchi...ally reduce the number of African children dying e...ree artemisinin-based combination therapies (ACT) ...ildren suspected of having malaria. This quick-res...etermine if it reduces the number of African child...
(Date:12/1/2008)...Toy Puppies to the Obama Daughters , , WASH... been made of President-Elect Obama,s first promis...ughter,s asthma and allergies, and timing issues, .... So, in the meantime, the Asthma and Allergy Fou...mp; allergy friendly" toy puppies to the Obama chi...
(Date:12/1/2008)...tomography (CT) colonography, also known as virtua... diseases at oncecolorectal cancer and osteoporosi...0. Results of the study will be presented today at... North America (RSNA). , "With CT colonography, ... were able to identify patients with osteoporosis,...
Breaking Medicine News(10 mins):Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 2Health News:Canada Supports Ground-Breaking Malaria Treatment Program in Sub-Saharan Africa 3Health News:Asthma and Allergy Foundation Helps New First-Dad Keep His First Promise 2Health News:CT colonography offers 1-stop screening for cancer and osteoporosis 2
...ain medications widely prescribed for rotator cuff...or cuff is composed of the muscles and tendons tha...it to the shoulder joint. The research involved 18...repair surgery. One-third of the rats were treated...
...antiretroviral therapy HAART, the cytomegalovirus ...ortunistic// infections that spread out of control...shorter time to death. Researchers assessed CMV s...HIV using a standard test. Investigators followed ...
...reened for cervical cancer, according to a new stu...routine // Pap smears are unnecessary for women wh...ancerous diseases. Since most of these women no lo...r cervical cancer. A survey done by researchers on...
...ption may be partly to blame for patients sufferin...ainly caused // by alcohol abuse and gall stones. ...nal pain, often accompanied by nausea and vomiting.... Researchers say pancreatitis has a poor prognosi...
Other Medicine News:
...The new Finnpipette Focus from Thermo Labsystems w...h uncompromising performance. Advanced features s...lume adjustment on microvolumes help to define thi...new interchangeable handle plate offers a custom f...
Enhanced drug and formulary reference with integrated ID treatment guide and tools. Increase patient safety and satisfaction with our premium drug reference.
Designed to inform decision making, PatientKeeper's Clinical Results delivers complete patient data on demand. Clinicians can rely on immediate access to lab results, medication profiles, microbiolog
The SJM Tailor annuloplasty ring, a fully flexible ring, is constructed of a barium-impregnated silicone strip covered with a knitted polyester sewing cuff.
Medicine Products: